Skip to content
ClinCalc Pro
Menu
Anticholinergic — Parkinson's Disease / Dystonia

Trihexyphenidyl

Brand names: Broflex

Trihexyphenidyl is an antimuscarinic (anticholinergic) agent used in Parkinson's disease, particularly for tremor, and to manage drug-induced extrapyramidal symptoms.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It blocks central muscarinic acetylcholine receptors, helping to redress the relative cholinergic excess that results from dopamine deficiency or dopamine-receptor blockade in the basal ganglia.

Prescribing in practice

  • Antimuscarinic effects make it hazardous in the elderly and it should be avoided where there is cognitive impairment, narrow-angle glaucoma, urinary retention or significant prostatic enlargement.
  • Confusion, hallucinations, dry mouth, blurred vision and constipation are common, especially in older patients.
  • It should be withdrawn gradually rather than stopped abruptly.

Monitoring

Monitor cognition, intraocular pressure where relevant, bowel and bladder function and overall antimuscarinic burden.

Counselling the patient

  • Report confusion, hallucinations, eye pain or difficulty passing urine.
  • Dry mouth and blurred vision are common; take care with tasks needing clear vision.

Evidence & guidelines

Its role in Parkinsonian tremor and drug-induced extrapyramidal symptoms is long established in clinical practice and standard references.

Reference: NICE NG71 (Parkinson's Disease); British Paediatric Neurology Association Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.